Establishing the Role of Tigecycline in an era of Antimicrobial Resistance

Jason J. Schafer; Debra A. Goff


Expert Rev Anti Infect Ther. 2008;6(5):557-567. 

In This Article


Tigecycline (Tygacil, Wyeth Pharmaceuticals, formally GAR-936) is the first glycylcycline antibiotic. It is structurally derived from minocycline but modified to provide a broad spectrum of antibacterial activity and an ability to overcome tetracycline-resistance mechanisms. Tigecycline displays in vitro activity against several Gram-positive, Gram-negative and anaerobic bacteria. It is extensively distributed in tissues. In the USA, it is currently indicated for the treatment of complicated intraabdominal infections (cIAIs) and complicated skin and skin-structure infections (cSSIs). Since US FDA and European Commission approval for these indications (June 2005 and May 2006, respectively), additional experiences with tigecycline have been reported. These include two Phase III clinical trials evaluating tigecycline for hospitalized patients with community-acquired pneumonia, clinical outcome studies of off-label indications and in vitro-susceptibility evaluations for drug-resistant Gram-positive and Gram-negative pathogens.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.